×


We Sell 100% ORIGINAL Books ONLY.

Computational Toxicology Risk Assessment For Chemicals at Meripustak

Computational Toxicology Risk Assessment For Chemicals by Sean Ekins, JOHN WILEY

Books from same Author: Sean Ekins

Books from same Publisher: JOHN WILEY

Related Category: Author List / Publisher List


  • Price: ₹ 14301.00/- [ 25.00% off ]

    Seller Price: ₹ 10725.00

Sold By: MeriPustak      Click for Bulk Order

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Estimated Delivery Time : 28-Oct-2021


Click for International Orders
  • We deliver across all postal codes in India

  • MeriPustak’s books are 100 % New & Original copy
  • General Information  
    Author(s)Sean Ekins
    PublisherJOHN WILEY
    Edition1st
    ISBN9781119282563
    Pages432
    BindingHardcover
    LanguageEnglish
    Publish YearFebruary 2018

    Description

    JOHN WILEY Computational Toxicology Risk Assessment For Chemicals by Sean Ekins

    A key resource for toxicologists across a broad spectrum of fields, this book offers a comprehensive analysis of molecular modelling approaches and strategies applied to risk assessment for pharmaceutical and environmental chemicals.

    •    Provides a perspective of what is currently achievable with computational toxicology and a view to future developments
    •    Helps readers overcome questions of data sources, curation, treatment, and how to model / interpret critical endpoints that support 21st century hazard assessment
    •    Assembles cutting-edge concepts and leading authors into a unique and powerful single-source reference
    •    Includes in-depth looks at QSAR models, physicochemical drug properties, structure-based drug targeting, chemical mixture assessments, and environmental modeling
    •    Features coverage about consumer product safety assessment and chemical defense along with chapters on open source toxicology and big data

    ABOUT THE AUTHOR:
    Sean Ekins, MSc, PhD, DSc has over 20 years of pharmaceutical and toxicology experience. He is the founder or co-founder of two companies and Adjunct Professor at three universities. He has been awarded 16 NIH grants as Principal Investigator. He has authored or co authored over 285 peer-reviewed papers and book chapters and edited five books with Wiley. His research is focused on collaborations to facilitate rare and neglected disease drug discovery.